Ann: Quarterly Activity Report & Appendix 4C - 30 June 2020, page-22

As an example only - ramping production up from 250,000 to 500,000 per month is barely enough to cater for the state of Victoria, let alone Australia, or the 7.8 billion people around the world. There are other players our there, and I'm sure investors have factored this in when deciding whether or not to buy AT1 today.

I think in August (thought they originally said July?), when we get the production increase update, and if AT1 announce who the North American partners are (we desperately need partners other than NG Biotech for these covid19 test kits), then it should be entice more investors. The key is to capitalize on this covid19 market if we are to see any immediately SP rise.

The future seems okay, with the HIV Self Test kits and OEM product sales and that should be something that long term holders can look forward to.